Article Per Year (5 Year)
p-Index From 2020 - 2025
0
P-Index
This Author published in this journals
All Journal The Journal of Experimental Life Sciences (JELS)
Sutiman B. Sumitro
Dept. of Biology, University of Brawijaya
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
EMSA Eritin Blocks Nuclear Factor-Kappa B in Diabetes Mellitus Mice Model Maic Audo Lin Sihombing; Sutiman B. Sumitro; Muhaimin Rifa'i
The Journal of Experimental Life Science Vol. 5 No. 1 (2015)
Publisher : Postgraduate School, Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1025.231 KB) | DOI: 10.21776/ub.jels.2015.005.01.05

Abstract

Diabetes mellitus is one of the common metabolic disorders with increasing prevalence during recent years with hyperglycemia as its characteristic. DM has been shown to be a state of free radicals over production resulted from hyperglycemia that can activate cellular signaling pathways transcription of factor NF-κB which stimulates the production of several inflammatory mediators andl lead to chronic inflammation. Chronic inflammation is implicated in β-cell damage and function and promotes apoptosis. EMSA Eritin is a polyherbal consisting of soy bean extracts, coconut water extract and red rice extract that assumed to be antidiabetic and anti-inflammatory. This study will assess the effectiveness of EMSA Eritin against inflammation in diabetes mellitus by measuring levels of NF-κB produced by immunocompetent cells in DM mice model. Streptozotocin 100 mg.kg-1 BW is used to induce diabetes mellitus in mice. Oral administration of EMSA Eritin was given for 14 days with dose of 0.3125 mg.g-1 BW, 3.125 mg.g-1 BW and 31.25 mg.g-1 BW. Data were analyzed using One-way ANOVA (p<0.05) and Duncan test using SPSS 16.0 for Windows. The results showed that EMSA Eritin can be used as an alternative therapy for the treatment of DM. The level of NF-κB in diabetic mice significantly decreased when the mice received EMSA Eritin. Keywords: Diabetes Mellitus, EMSA Eritin, NF-κB, ROS
Co-Authors Maic Audo Lin Sihombing Muhaimin Rifa'i